CY1111925T1 - Κιναση της θυμιδινης - Google Patents

Κιναση της θυμιδινης

Info

Publication number
CY1111925T1
CY1111925T1 CY20111100964T CY111100964T CY1111925T1 CY 1111925 T1 CY1111925 T1 CY 1111925T1 CY 20111100964 T CY20111100964 T CY 20111100964T CY 111100964 T CY111100964 T CY 111100964T CY 1111925 T1 CY1111925 T1 CY 1111925T1
Authority
CY
Cyprus
Prior art keywords
nucleotides
thymidine
movement
polynucleotide
replaced
Prior art date
Application number
CY20111100964T
Other languages
English (en)
Original Assignee
Molmed Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32750189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111925(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Molmed Spa filed Critical Molmed Spa
Publication of CY1111925T1 publication Critical patent/CY1111925T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Ένα πολυνουκλεοτίδιο που περιλαμβάνει μια αλληλουχία νουκλεοτιδίων που κωδικοποιεί μια κινάση της θυμιδίνης όπου τουλάχιστον ένα από τα νουκλεοτίδια που αντιστοιχεί στα νουκλεοτίδια της θέσης ματίσματος του δότη αντικαθίσταται από ένα άλλο νουκλεοτίδιο και όπου τα νουκλεοτίδια των θέσεων ματίσματος του λήπτη δεν είναι αλλοιωμένα.
CY20111100964T 2004-06-18 2011-10-10 Κιναση της θυμιδινης CY1111925T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413702.2A GB0413702D0 (en) 2004-06-18 2004-06-18 Thymidine kinase
EP05766582A EP1781789B1 (en) 2004-06-18 2005-06-17 Thymidine kinase

Publications (1)

Publication Number Publication Date
CY1111925T1 true CY1111925T1 (el) 2015-11-04

Family

ID=32750189

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100964T CY1111925T1 (el) 2004-06-18 2011-10-10 Κιναση της θυμιδινης
CY2016054C CY2016054I1 (el) 2004-06-18 2016-12-28 Κιναση της θυμιδινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2016054C CY2016054I1 (el) 2004-06-18 2016-12-28 Κιναση της θυμιδινης

Country Status (20)

Country Link
US (5) US8357788B2 (el)
EP (1) EP1781789B1 (el)
JP (1) JP5091669B2 (el)
KR (1) KR101337210B1 (el)
CN (1) CN101010428B (el)
AT (1) ATE520779T1 (el)
AU (1) AU2005254807B2 (el)
CA (1) CA2569304C (el)
CY (2) CY1111925T1 (el)
DK (1) DK1781789T3 (el)
ES (1) ES2372022T3 (el)
GB (1) GB0413702D0 (el)
HU (1) HUS1600064I1 (el)
IL (2) IL179660A (el)
LT (1) LTC1781789I2 (el)
NL (1) NL300856I2 (el)
PL (1) PL1781789T3 (el)
PT (1) PT1781789E (el)
SI (1) SI1781789T1 (el)
WO (1) WO2005123912A2 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase
CN103842501B (zh) 2011-10-05 2017-12-08 莫尔梅德股份有限公司 病毒载体纯化系统
US11857585B2 (en) 2017-12-28 2024-01-02 Bionoxx Inc. Oncolytic virus improved in safety and anticancer effect
US11157042B1 (en) 2018-03-28 2021-10-26 Douglas Patton Systems and methods for interaction of wearable communication devices
KR20210016567A (ko) 2018-05-30 2021-02-16 글리코스템 떼라퓨틱스 비.브이. Car nk 세포
JP7704419B2 (ja) * 2019-06-27 2025-07-08 バイオノックス インコーポレイテッド 安全性及び抗がん効果が改善された腫瘍溶解性ウイルス
WO2025168661A1 (en) 2024-02-05 2025-08-14 Ospedale San Raffaele S.R.L. Chimeric antigen receptor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033975T2 (de) 1989-01-23 2002-10-02 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanttherapien für Infektionen und hyperproliferative Störungen
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
IT1261847B (it) 1993-09-01 1996-06-03 San Romanello Centro Fond Metodo per marcare cellule eucariote.
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
AU2434195A (en) 1994-05-02 1995-11-29 University Of Washington Thymidine kinase mutants
HUP9902571A3 (en) * 1996-02-09 2002-01-28 Gencell Sa Variants of thymidine kinase, related nucleic acids sequences and their use in genic therapy
FR2751988B1 (fr) 1996-08-01 1998-09-11 Rhone Poulenc Rorer Sa Nouveaux variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
FR2744731B1 (fr) 1996-02-09 1998-05-22 Rhone Poulenc Rorer Sa Nouveaux variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
EP0954222A4 (en) 1996-04-10 2003-01-15 Univ Southern California GENE THERAPY FOR PROLIFERATIVE VITREORETINOPATHY
AU3889197A (en) 1996-07-26 1998-02-20 Douglas V Faller Compositions comprising an inducing agent and an anti-viral agent for the treat ment of blood, viral and cellular disorders
JP2002516061A (ja) 1997-10-14 2002-06-04 ダーウィン モレキュラー コーポレイション チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質
GB0008966D0 (en) * 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
CN1273587C (zh) * 2002-06-05 2006-09-06 上海新世界基因技术开发有限公司 疱疹病毒胸苷激酶突变体及其应用
EP1428886B1 (de) * 2002-12-09 2009-08-05 Celltech GmbH Biotechnologie Verbesserte retrovirale Vektoren für die Gentherapie
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase

Also Published As

Publication number Publication date
WO2005123912A2 (en) 2005-12-29
IL179660A0 (en) 2007-05-15
EP1781789A2 (en) 2007-05-09
AU2005254807B2 (en) 2011-08-18
US20090130069A1 (en) 2009-05-21
CA2569304C (en) 2014-08-12
LTPA2016047I1 (lt) 2017-01-25
CN101010428A (zh) 2007-08-01
EP1781789B1 (en) 2011-08-17
DK1781789T3 (da) 2011-11-28
US20190070312A1 (en) 2019-03-07
JP5091669B2 (ja) 2012-12-05
KR20070032786A (ko) 2007-03-22
ES2372022T3 (es) 2012-01-13
PL1781789T3 (pl) 2011-12-30
SI1781789T1 (sl) 2012-03-30
US20150231275A1 (en) 2015-08-20
PT1781789E (pt) 2011-10-20
AU2005254807A1 (en) 2005-12-29
IL179660A (en) 2012-12-31
CY2016054I2 (el) 2017-07-12
IL213084A0 (en) 2011-07-31
ATE520779T1 (de) 2011-09-15
US9005945B2 (en) 2015-04-14
WO2005123912A3 (en) 2006-05-04
CN101010428B (zh) 2013-10-02
HUS1600064I1 (hu) 2017-02-28
LTC1781789I2 (lt) 2018-10-10
NL300856I2 (el) 2017-04-20
JP2008502342A (ja) 2008-01-31
KR101337210B1 (ko) 2013-12-06
US20130028876A1 (en) 2013-01-31
US20140178345A1 (en) 2014-06-26
US8642311B2 (en) 2014-02-04
HK1097881A1 (en) 2007-07-06
US10155052B2 (en) 2018-12-18
CY2016054I1 (el) 2017-07-12
CA2569304A1 (en) 2005-12-29
US10314925B2 (en) 2019-06-11
GB0413702D0 (en) 2004-07-21
US8357788B2 (en) 2013-01-22

Similar Documents

Publication Publication Date Title
CY1111925T1 (el) Κιναση της θυμιδινης
CY2018019I1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
DK3587433T3 (da) Modificerede nukleotider
CY2016052I2 (el) Τροποποιημενα φθοριομενα αναλογα νουκλεοζιδιων
CY1117139T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις πρωτεϊνης κινασης τυροσινης
CY1117820T1 (el) Δικυκλικες ετερο-κυκλικες ενωσεις σαν καταστολεις κινασης (kinase) πρωτεϊνης
DK3266791T3 (da) Mærkede nukleotider
ATE474614T1 (de) Verbesserter pen-injektor
DE602005021040D1 (de) Elektrochirurgisches System mit Vielzahl von Elektroden
DK2354148T3 (da) Nukleosidanaloger og oligonukleotiderivate omfattende nukleotidanalog deraf
DE602005020229D1 (de) Schaufel mit prallgekühltem Übergang von grossem Krümmungsradius
BRPI0412856A2 (pt) trava extensível de múliplos pontos aperfeiçoada
NO20054405D0 (no) Kjemokinreseptor-binende heterosykel
CR8385A (es) Pirimidinas sustituidas con sulfoximina como inhibidores de cdk y/o vegf, su preparacion y sus usos como medicamento
CY1117599T1 (el) Σουλφοναμιδια για την προληψη του διαβητη
DE602004017676D1 (de) Mit Peroxiden haertbare Butylformulierungen
DE602004029903D1 (de) Tunnelübergangselement
DE502004003472D1 (de) Zusammensetzung auf basis von polycarbonaten
FR2853906B1 (fr) N-desoxyribosyltransferases de lactobacilles, sequences nucleotidiques correspondantes et leurs applications
ITPD20030145A1 (it) Pannello touch control di tipo capacitivo particolarmente,
BR8202159Y1 (pt) disposição construtiva aplicada em tijolo.
ITPD20030144A1 (it) Pannello di comando touch control di tipo capacitivo
SE0303084D0 (sv) Method to produce nucleotide sequence molecules
FI20030211A0 (fi) Pohjalevytön kalliokärki
SE0202180D0 (sv) Manuell ampullknäckare